Dietary agents for prostate cancer chemoprevention: An overview

Current Cancer Therapy Reviews

Volumn 6, Issue 4, 2010, Pages 308-316

  Venier, Natalie A ^a   Klotz, Laurence H ^a   Fleshner, Neil E ^b   Venkateswaran, Vasundara ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Clinical trials; Diet; Flavonoids; In vivo; Micronutrients; Prostate cancer

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; CURCUMIN; ELLAGIC ACID; EPIGALLOCATECHIN; FLAVONOID; GENISTEIN; LYCOPENE; NATURAL PRODUCT; POLYPHENOL; PROSTATE SPECIFIC ANTIGEN; RESVERATROL; SELENIUM; SELENOMETHIONINE; SILIBININ; SILYMARIN; SOMATOMEDIN BINDING PROTEIN 1; TRACE ELEMENT; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CHEMOPROPHYLAXIS; CYTOTOXICITY; DIETARY INTAKE; DIETARY SUPPLEMENT; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; EARLY CANCER; FAT INTAKE; GENE EXPRESSION ASSAY; HUMAN; LIFESTYLE MODIFICATION; MACRONUTRIENT; NONHUMAN; NUTRITION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SCREENING TEST; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

EID: 84937516061     PISSN: 15733947     EISSN: 18756301     Source Type: Journal    
DOI: 10.2174/157339410793358093     Document Type: Article

References (92)

1. Canadian Cancer Society. Prostate Cancer Statistics 2009.
2. Nogueira L, Corradi R, Eastham JA. Prostatic specific antigen for prostate cancer detection. Int Braz J Urol 2009 35(5): 521-9.
3. Lieberman R. Chemoprevention of prostate cancer: current status and future directions. Cancer Metastasis Rev 2002; 21(3-4): 297-309.
4. Joshua AM, Evans A, Van der KT, et al. Prostatic preneoplasia and beyond. Biochim Biophys Acta 2008; 1785(2): 156-81.
5. American Cancer Society. Am Can Soc: Statistics 2008-2009.
6. Fair WR, Fleshner NE, Heston W. Cancer of the prostate: a nutritional disease? Urology 1997; 50(6): 840-8.
7. Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer: Geographical distribution and time-trends. Acta Oncol 1991; 30(2): 133-40.
8. Ornish D, Magbanua MJ, Weidner G, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci USA 2008; 105(24): 8369-74.
9. Kenfield SA, Chang ST, Chan JM. Diet and lifestyle interventions in active surveillance patients with favorable-risk prostate cancer. Curr Treat Options Oncol 2007; 8(3): 173-96.
10. Kobayashi N, Barnard RJ, Said J, et al. Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res 2008; 68(8): 3066-73.
11. Bidoli E, Talamini R, Bosetti C, et al. Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann Oncol 2005; 16(1): 152-7.
12. Venkateswaran V, Haddad AQ, Fleshner NE, et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 2007; 99(23): 1793-800.
13. Guaiquil VH, Vera JC, Golde DW. Mechanism of vitamin C inhibition of cell death induced by oxidative stress in glutathione-depleted HL-60 cells. J Biol Chem 2001; 276(44): 40955-61.
14. Liu RH. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 2004; 134(12 Suppl): 3479S-85S.
15. Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, Klotz LH. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 2006; 9(1): 68-76.
16. Katz A. Advances in Prostate Cancer Chemoprevention and Treatment. Life Extension Report 2007.
17. Klotz L. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention. Nat Clin Pract Urol 2008; 5(1): 2-3.
18. Klotz L. Active surveillance for prostate cancer: trials and tribulations. World J Urol 2008; 26(5): 437-42.
19. Klotz L. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nat Clin Pract Urol 2005; 2(3): 136-42.
20. Tsuda H, Ohshima Y, Nomoto H, et al. Cancer prevention by natural compounds. Drug Metab Pharmacokinet 2004; 19(4): 245-63.
21. van Breemen RB, Pajkovic N. Multitargeted therapy of cancer by lycopene. Cancer Lett 2008; 269(2): 339-51.
22. Guns ES, Cowell SP. Drug Insight: lycopene in the prevention and treatment of prostate cancer. Nat Clin Pract Urol 2005; 2(1): 38-43.
23. Ferreira AL, Yeum KJ, Liu C, et al. Tissue distribution of lycopene in ferrets and rats after lycopene supplementation. J Nutr 2000; 130(5): 1256-60.
24. Herzog A, Siler U, Spitzer V, et al. Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 2005; 19(2): 272-4.
25. Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 2004; 64(16): 5891-6.
26. Venkateswaran V, Klotz LH, Ramani M, et al. A combination of micronutrients is beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady transgenic model. Cancer Prev Res (Phila Pa) 2009; 2(5): 473-83.
27. Hantz HL, Young LF, Martin KR. Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med (Maywood) 2005; 230(3): 171-9.
28. Ivanov NI, Cowell SP, Brown P, Rennie PS, Guns ES, Cox ME. Lycopene differentially induces quiescence and apoptosis in androgen-responsive and-independent prostate cancer cell lines. Clin Nutr 2007; 26(2): 252-63.
29. Kanagaraj P, Vijayababu MR, Ravisankar B, Anbalagan J, Aruldhas MM, Arunakaran J. Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells. J Cancer Res Clin Oncol 2007; 133(6): 351-9.
30. Liu X, Allen JD, Arnold JT, Blackman MR. Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells. Carcinogenesis 2008; 29(4): 816-23.
31. Ablin RJ. Lycopene: a word of caution. Am J Health Syst Pharm 2005 62(9): 899.
32. Ni J, Yeh S. The roles of alpha-vitamin E and its analogues in prostate cancer. Vitam Horm 2007; 76: 493-518.
33. Venkateswaran V, Fleshner NE, Klotz LH. Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol 2002; 168(4 Pt 1): 1578-82.
34. Conte C, Floridi A, Aisa C, Piroddi M, Floridi A, Galli F. Gamma-tocotrienol metabolism and antiproliferative effect in prostate cancer cells. Ann N Y Acad Sci 2004; 1031: 391-4.
35. Jiang Q, Wong J, Fyrst H, Saba JD, Ames BN. gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. Proc Natl Acad Sci USA 2004; 101(51): 17825-30.
36. Ni J, Wen X, Yao J, et al. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. Cancer Res 2005; 65(21): 9807-16.
37. Syed DN, Suh Y, Afaq F, Mukhtar H. Dietary agents for chemoprevention of prostate cancer. Cancer Lett 2008; 265(2): 167-76.
38. Fleshner N, Fair WR, Huryk R, Heston WD. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol 1999; 161(5): 1651-4.
39. th ed. Thomson Learning, Inc.; 2005.
40. Nomura AM, Lee J, Stemmermann GN, Combs GF, Jr. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000; 9(9): 883-7.
41. Yoshizawa K, Ascherio A, Morris JS, et al.Prospective study of selenium levels in toenails and risk of coronary heart disease in men. Am J Epidemiol 2003; 158(9): 852-60.
42. Venkateswaran V, Klotz LH, Fleshner NE. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 2002; 62(9): 2540-5.
43. Zhao R, Xiang N, Domann FE, Zhong W. Expression of p53 enhances selenite-induced superoxide production and apoptosis in human prostate cancer cells. Cancer Res 2006; 66(4): 2296-304.
44. Wu Y, Zhang H, Dong Y, Park YM, Ip C. Endoplasmic reticulum stress signal mediators are targets of selenium action. Cancer Res 2005; 65(19): 9073-9.
45. Wu Y, Zu K, Warren MA, Wallace PK, Ip C. Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells. Mol Cancer Ther 2006; 5(2): 246-52.
46. Combs GF, Jr, Clark LC, Turnbull BW. Reduction of cancer mortality and incidence by selenium supplementation. Med Klin (Munich) 1997; 92: 42-5.
47. Combs GF, Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther 1998; 79(3): 179-92.
48. D'Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005; 55(5): 319-21.
49. Tabassum A, Bristow R.G, Venkateswaran V. Ingestion of selenium and other antioxidants during prostate cancer radiotherapy: a good thing? Cancer Treat Rev 2010; 36(3): 230-4.
50. El Touny LH, Banerjee PP. Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res 2009; 69(8): 3695-703.
51. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008; 269(2): 226-42.
52. Rao A, Coan A, Welsh JE, Barclay WW, Koumenis C, Cramer SD. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res 2004; 64(6): 2143-7.
53. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001; 98(18): 10350-5.
54. Adhami VM, Siddiqui IA, Sarfaraz S, et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res 2009; 15(6): 1947-53.
55. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 2007; 6(10): 2696-707.
56. Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 2008; 14(23): 7773-80.
57. Wang TT, Hudson TS, Wang TC, et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 2008; 29(10): 2001-10.
58. Harper CE, Patel BB, Wang J, Arabshahi A, Eltoum IA, Lamartiniere CA. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 2007; 28(9): 1946-53.
59. Ratan HL, Steward WP, Gescher AJ, Mellon JK. Resveratrol--a prostate cancer chemopreventive agent? Urol Oncol 2002; 7(6): 223-7.
60. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila Pa) 2009; 2(5): 409-18.
61. Seeni A, Takahashi S, Takeshita K, et al. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 2008; 9(1): 7-14.
62. Bell C, Hawthorne S. Ellagic acid, pomegranate and prostate cancer--a mini review. J Pharm Pharmacol 2008; 60(2): 139-44.
63. Malik A, Mukhtar H. Prostate cancer prevention through pomegranate fruit. Cell Cycle 2006; 5(4): 371-3.
64. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71(10): 1397-421.
65. Li TM, Chen GW, Su CC, et al. Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res 2005; 25(2A): 971-9.
66. Rettig MB, Heber D, An J, et al. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther 2008; 7(9): 2662-71.
67. Hong MY, Seeram NP, Heber D. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J Nutr Biochem 2008; 19(12): 848-55.
68. Sartippour MR, Seeram NP, Rao JY, et al. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol 2008; 32(2): 475-80.
69. Kimlin MG. Geographic location and vitamin D synthesis. Mol Aspects Med 2008; 29(6): 453-61.
70. de Vries E, Soerjomataram I, Houterman S, Louwman MW, Coebergh JW. Decreased risk of prostate cancer after skin cancer diagnosis: a protective role of ultraviolet radiation? Am J Epidemiol 2007; 165(8): 966-72.
71. Gupta D, Lammersfeld CA, Trukova K, Lis CG. Vitamin D and prostate cancer risk: a review of the epidemiological literature. Prostate Cancer Prostatic Dis 2009; 12(3): 215-26.
72. Rukin NJ, Zeegers MP, Ramachandran S, et al. A comparison of sunlight exposure in men with prostate cancer and basal cell carcinoma. Br J Cancer 2007; 96(3): 523-8.
73. Ahn J, Albanes D, Berndt SI, et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 2009; 30(5): 769-76.
74. Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15(2): 203-10.
75. Shankar S, Srivastava RK. Bax and Bak genes are essential for maximum apoptotic response by curcumin, a polyphenolic compound and cancer chemopreventive agent derived from turmeric, Curcuma longa. Carcinogenesis 2007; 28(6): 1277-86.
76. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett 2007; 255(2): 170-81.
77. Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 2007; 30(4): 905-18.
78. Barve A, Khor TO, Hao X, et al. Murine prostate cancer inhibition by dietary phytochemicals--curcumin and phenyethylisothio-cyanate. Pharm Res 2008; 25(9): 2181-9.
79. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87(23): 1767-76.
80. Mucci LA, Tamimi R, Lagiou P, et al. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 2001; 87(9): 814-20.
81. Schwarz S, Obermuller-Jevic UC, Hellmis E, Koch W, Jacobi G, Biesalski HK. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 2008; 138(1): 49-53.
82. Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001; 93(24): 1872-9.
83. Heber D. Multitargeted therapy of cancer by ellagitannins. Cancer Lett 2008; 269(2): 262-8.
84. Pantuck AJ, Leppert JT, Zomorodian N, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006; 12(13): 4018-26.
85. Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007; 25(2): 139-46.
86. Clark LC, Combs GF, Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276(24): 1957-63.
87. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90(6): 440-6.
88. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the selenium and vitamin E cancer prevention trial. Urol Oncol 2003; 21(1): 59-65.
89. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301(1): 39-51.
90. Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005; 97(2): 94-102.
91. Hatfield DL, Gladyshev VN. The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. Mol Interv 2009; 9(1): 18-21.
92. Scott EN, Gescher AJ, Steward WP, Brown K. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila Pa) 2009; 2(6): 525-30.